Humacyte to Present at the 37th Annual J.P.Morgan Healthcare Conference
Humacyte to Present at the 37th Annual J.P.Morgan Healthcare Conference
Jan 7, 2019
RESEARCH TRIANGLE PARK, N.C. – January 7, 2019. Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 8,2019 at 9:00 a.m. Pacific Time.
ABOUT HUMACYTE
Humacyte, Inc., a privately held company founded by Dr. Laura E. Niklason, M.D., Ph.D., in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many speci?c applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.
Contacts
Douglas Blankenship
919.313.9633
dblankenship@humacyte.com
Westwicke Partners
Mike Piccinino
443.213.0509
mike.piccinino@westwicke.com
ICR, PR for Humacyte
Nirav Suchak
646.277.1257
Nirav.Suchak@icrinc.com
ABOUT HUMACYTE
Humacyte, Inc., a privately held company founded by Dr. Laura E. Niklason, M.D., Ph.D., in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many speci?c applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.
Contacts
Douglas Blankenship
919.313.9633
dblankenship@humacyte.com
Westwicke Partners
Mike Piccinino
443.213.0509
mike.piccinino@westwicke.com
ICR, PR for Humacyte
Nirav Suchak
646.277.1257
Nirav.Suchak@icrinc.com